Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Outlook Therapeutics Inc (OTLK)

Outlook Therapeutics Inc (OTLK)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 34,065
  • Shares Outstanding, K 23,656
  • Annual Sales, $ 0 K
  • Annual Income, $ -58,980 K
  • EBIT $ -61 M
  • EBITDA $ -61 M
  • 60-Month Beta 0.46
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 282.35% ( -3.05%)
  • Historical Volatility 309.94%
  • IV Percentile 97%
  • IV Rank 81.47%
  • IV High 339.69% on 11/25/24
  • IV Low 30.26% on 09/16/24
  • Put/Call Vol Ratio 0.00
  • Today's Volume 133
  • Volume Avg (30-Day) 1,676
  • Put/Call OI Ratio 0.00
  • Today's Open Interest 26,135
  • Open Int (30-Day) 18,410

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/24
See More
  • Average Estimate -0.83
  • Number of Estimates 3
  • High Estimate -0.76
  • Low Estimate -0.89
  • Prior Year -1.00
  • Growth Rate Est. (year over year) +17.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.8700 +65.52%
on 11/27/24
5.2900 -72.78%
on 11/21/24
-3.8400 (-72.73%)
since 11/20/24
3-Month
0.8700 +65.52%
on 11/27/24
6.9800 -79.37%
on 11/07/24
-4.5600 (-76.00%)
since 09/20/24
52-Week
0.8700 +65.52%
on 11/27/24
12.8499 -88.79%
on 04/01/24
-6.9360 (-82.81%)
since 12/20/23

Most Recent Stories

More News
Have a Relaxing Holiday Season

Monday U.S. Economic Lookahead Consumer confidence (Dec.) Featured Earnings Limoneira ...

OTLK : 1.4400 (+3.60%)
PFX : 49.70 (+0.61%)
LMNR : 26.30 (+2.49%)
CVM : 0.7299 (-4.60%)
Outlook Therapeutics Implements Organizational Streamlining Measures Ahead of LYTENAVAâ„¢ Launch in EU and UK

Outlook Therapeutics announces strategic workforce reduction to enhance resource allocation for launching LYTENAVAâ„¢ in Europe and UK.Quiver AI SummaryOutlook Therapeutics, Inc. has announced strategic...

OTLK : 1.4400 (+3.60%)
Outlook Therapeutics® Streamlines Operations

OTLK : 1.4400 (+3.60%)
OTLKW : 0.03 (-1.96%)
Outlook Therapeutics® Announces NICE Recommendation of LYTENAVA™ (bevacizumab gamma) for the Treatment of Wet AMD

OTLK : 1.4400 (+3.60%)
OTLKW : 0.03 (-1.96%)
Outlook Therapeutics Announces Leadership Change; Russell Trenary Steps Down as CEO

Outlook Therapeutics announces CEO transition; Lawrence Kenyon appointed Interim CEO as company prepares for LYTENAVAâ„¢ launch in 2025.Quiver AI SummaryOutlook Therapeutics, Inc. announced that Russell...

OTLK : 1.4400 (+3.60%)
Outlook Therapeutics® Announces Executive Leadership Transition

OTLK : 1.4400 (+3.60%)
OTLKW : 0.03 (-1.96%)
Outlook Therapeutics Announces Preliminary Results from NORSE EIGHT Trial and Plans for BLA Resubmission in Early 2025

Outlook Therapeutics reports preliminary results for ONS-5010 in wet AMD, planning BLA resubmission in early 2025.Quiver AI SummaryOutlook Therapeutics, Inc. announced preliminary topline results from...

OTLK : 1.4400 (+3.60%)
Outlook Therapeutics® Announces Preliminary Topline Results of NORSE EIGHT Clinical Trial

OTLK : 1.4400 (+3.60%)
OTLKW : 0.03 (-1.96%)
Outlook Therapeutics® to Present at the Guggenheim Healthcare Innovation Conference

OTLK : 1.4400 (+3.60%)
OTLKW : 0.03 (-1.96%)
Outlook Therapeutics® Participates in a Virtual Investor CEO Connect Segment

OTLK : 1.4400 (+3.60%)
OTLKW : 0.03 (-1.96%)

Business Summary

Outlook Therapeutics Inc. is a clinical-stage biopharmaceutical company. It focuses on developing ONS-5010 which is a proprietary ophthalmic bevacizumab product candidate for the treatment of wet age related macular degeneration which is in clinical stage. Outlook Therapeutics Inc., formerly known as...

See More

Key Turning Points

3rd Resistance Point 1.6284
2nd Resistance Point 1.5492
1st Resistance Point 1.4946
Last Price 1.4400
1st Support Level 1.3608
2nd Support Level 1.2816
3rd Support Level 1.2270

See More

52-Week High 12.8499
Fibonacci 61.8% 8.2736
Fibonacci 50% 6.8600
Fibonacci 38.2% 5.4463
Last Price 1.4400
52-Week Low 0.8700

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar